Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most interaction and warning statements broadly align with label sections provided (grapefruit, CYP3A4 inhibitors, cyclosporine, liver function testing). However, several claims are partially mismatched or not fully supported by the supplied label excerpts (e.g., alcohol and supplements language; liver-symptom examples; monitoring wording about “if ordered”; lifestyle/“dose escalation” framing), and some precautions are not supported with specificity from the provided text.
Category Scores
Accurate Statements
Grapefruit and grapefruit juice should be avoided or limited because grapefruit can increase atorvastatin exposure and raise the risk of side effects, especially muscle-related problems.
Supported by label 7.2: grapefruit juice can increase plasma concentrations of atorvastatin, especially with excessive consumption (>1.2 liters/day). Label excerpt also links strong CYP3A4 inhibitors (category includes grapefruit components) to increased risk of myopathy/skeletal muscle effects (5.1; 7).
Gemfibrozil (used for triglycerides) can interact strongly with atorvastatin and increase the risk of side effects.
Supported in label 7 (risk of myopathy increased with concurrent administration of fibric acid derivatives). Gemfibrozil is a fibric acid derivative.
Cyclosporine can interact strongly with atorvastatin and increase the risk of side effects.
Supported by label 7 and 7.3: risk of myopathy increased with cyclosporine; and dose should not exceed 10 mg if co-administered.
Strong CYP3A4 inhibitors can raise atorvastatin levels and increase the risk of muscle toxicity.
Supported by label 5.1 and 7: risk of myopathy increased with strong CYP3A4 inhibitors; label gives examples (clarithromycin, HIV protease inhibitors, itraconazole) and notes AUC increase and caution when dose exceeds 20 mg (7.1).
New, unexplained muscle pain, tenderness, weakness, or dark/tea-colored urine can be signs of serious muscle injury in people taking atorvastatin.
Label 5.1 describes rhabdomyolysis/myopathy risk in the context of statins and mentions myoglobinuria (myopathy/rhabdomyolysis secondary to myoglobinuria). The specific symptom list is not quoted, but the concept of serious muscle injury consistent with myopathy/rhabdomyolysis is supported.
New muscle symptoms after starting or increasing an atorvastatin dose should be reported.
Label 5.1 states LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor. The label excerpt does not explicitly say “after starting or increasing,” but it supports the need for clinical action for suspected myopathy.
After a missed atorvastatin dose, the patient should not double up without guidance.
Not directly supported in the provided label excerpts (no missed-dose/doubling guidance text included).
Before starting atorvastatin (or starting a new prescription or supplement), clinicians/pharmacists should have a current list of all medications and supplements (including OTC products).
Not directly supported in the provided label excerpts (no “current medication list/OTC” workflow language included).
Before starting atorvastatin (or starting a new prescription or supplement), clinicians/pharmacists should know the patient’s history of liver disease or prior muscle problems on statins.
Partially supported: label 4.1 contraindication for active liver disease and label 5.1 includes risk-factor awareness for myopathy; however, no explicit “prior muscle problems on statins” counseling/workflow is stated in the excerpts.
Before starting atorvastatin (or starting a new prescription or supplement), clinicians/pharmacists should know any recent changes in the patient’s medication regimen.
Not directly supported in provided excerpts (no explicit recent-change counseling language).
Unsupported Statements
Heavy alcohol use should be avoided or kept moderate because large alcohol intake can increase the risk of liver problems and may make it harder to manage medication safety.
No alcohol-use counseling language appears in the provided label excerpts (contraindications/warnings include active liver disease and liver enzyme monitoring, but not alcohol quantity advice).
Certain antibiotics and antifungals (macrolide and azole antifungal classes) can interact strongly with atorvastatin and increase the risk of side effects.
Label 7.1 provides examples (clarithromycin; itraconazole) as strong CYP3A4 inhibitors increasing myopathy risk. The claim generalizes to ‘macrolide’ and ‘azole antifungal classes’; the excerpts specifically name clarithromycin and itraconazole rather than all in those classes.
Some HIV antivirals can interact strongly with atorvastatin and increase the risk of side effects.
Label 7.1 mentions HIV protease inhibitors as strong CYP3A4 inhibitors requiring caution; the claim is class-level and is supported in principle but not specified which HIV antivirals beyond “protease inhibitors” in excerpts.
Some over-the-counter supplements can interact or affect liver/muscle risk in people taking atorvastatin.
No OTC supplements guidance or specific supplement interactions are included in the provided label excerpts.
Symptoms of liver trouble in people taking atorvastatin include unusual fatigue, loss of appetite, right upper belly pain, dark urine, or yellowing of the skin/eyes.
Label excerpt 5.2 describes biochemical liver function abnormalities and monitoring; no specific symptom list is provided.
Scheduled liver and cholesterol monitoring should not be skipped if ordered by the prescriber.
Label 5.2 supports liver function tests prior to and at 12 weeks after initiation and at 12 weeks following dose elevation; the excerpt does not mention 'should not be skipped if ordered' nor any cholesterol-monitoring directive.
Continuing heavy saturated fat intake, smoking, and inactivity can undermine cholesterol treatment with atorvastatin and lead to unnecessary dose escalation.
The label 1 includes diet as an adjunct and that therapy should be part of multiple risk factor intervention, but no statement about smoking/inactivity causing 'dose escalation' appears in the provided excerpts.
After a missed atorvastatin dose, the patient should not double up without guidance.
No missed-dose instruction text appears in provided label excerpts.
The patient should not change the atorvastatin dose on their own because side effects can be dose- or interaction-related and may be managed by adjusting the plan.
Label excerpts include titration/dosing range and cautions about drug interactions, but do not include specific patient instruction text about not changing dose independently.
Contradictions
Important Omissions
If a claim implies or involves dosing safety in interacting patients (e.g., cyclosporine or strong CYP3A4 inhibitors), the label provides specific dose-limiting cautions (e.g., cyclosporine: limit to 10 mg once daily; strong CYP3A4 inhibitors: caution when dose exceeds 20 mg). Those specific numeric limitations were not included in the AI statements (except indirectly via 'strong interactions').
Importance:
Moderate
For liver monitoring, label 5.2 specifies timing (prior to and at 12 weeks after initiation and any elevation of dose) and defines action thresholds (persistent ALT/AST >3x ULN): reduction of dose or withdrawal. The AI did not mention these specifics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements align with labeled interaction risks (grapefruit/CYP3A4 inhibitors, cyclosporine, fibric acid derivatives) and muscle/liver safety concepts. However, unsupported generalizations (alcohol, OTC supplements, liver symptom examples), missing dose-limiting specifics, and unsourced monitoring/dosing behavior instructions reduce label fidelity; the risk of misinformation is therefore moderate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not directly supported by the provided label excerpts (especially alcohol/OTC supplements, specific liver symptom list, missed-dose/dose-change counseling, and the wording about monitoring being 'if ordered'). Some interaction statements are class-level generalizations that are only partially supported by named examples in the excerpts.
Suggested Improvement
Restrict statements to label-supported specifics: use the label’s named interaction examples (clarithromycin, itraconazole, HIV protease inhibitors), include label dose limits for cyclosporine (max 10 mg once daily) and caution thresholds for strong CYP3A4 inhibitor coadministration (caution when dose exceeds 20 mg), and align monitoring guidance to the label’s timing and ALT/AST threshold language. Remove or rephrase unsupported general counseling (alcohol, OTC supplements, symptom lists, missed-dose/doubling, and patient dose self-adjustment).